Abstract: Disclosed herein are system, method, and computer program product embodiments for training and deploying a machine learning model to generate an assessment of risks and mitigations in response to a novel initiative request. After generating labeled data from a corpus of prior risk assessments, a machine learning model may be trained to programmatically generate a risk assessment in response to a novel initiative request. The system may provide for centralized control over the creation, review, and approval of initiative requests. The system may further analyze consumer-facing applications deployed by an organization and train the machine learning model to algorithmically determine consumer-facing applications potentially affected by an initiative request.

Abstract: Disclosed herein are system, method, and computer program product embodiments for training and deploying a machine learning model to generate an assessment of risks and mitigations in response to a novel initiative request. After generating labeled data from a corpus of prior risk assessments, a machine learning model may be trained to programmatically generate a risk assessment in response to a novel initiative request. A risk auditor may subsequently review the risk assessment generated using the machine learning model to provide various feedback reflecting the accuracy of the risks and mitigations. The machine learning model may then be retrained based on the feedback provided by the risk auditor to provide more accurate risks and mitigations in response to future initiatives.

Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.

Abstract: Disclosed herein are system, method, and computer program product embodiments for executing automatic internet browsing sessions using pseudo-user profiles. In some embodiments, a plug-in integrated by a browser receives a request to execute an automated browsing session for the user profile. The plug-in retrieves a set of parameters associated with the user profile. The set of parameters comprise one or more rules for executing an automated browsing session. The plug-in executes the automated browsing session by automatically navigating to one or more websites, as indicated in the set of parameters. The plug-in interacts with the one or more websites based on the set of parameters.

Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.

Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.

Abstract: A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions, said substituted derivatives having the general formula

Abstract: A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Abstract: The instant invention is a route to stereospecific 3-substituted 5-membered ring isomers of Formula (A). The final products are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammation especially arthritis, sleep disorders, premenstrual syndrome, and hot flashes. The invention provides novel routes to synthesize steroselectively analogs of gabapentin (Neurontin®) of Formulas (I), (II), (III) and (IV) wherein R is C1-C10 alkyl or C3-C10 cycloalkyl and pharmaceutically acceptable salts thereof.

Abstract: A process for joining at least two substrates together comprises applying between the substrates a composition comprising a liquid pre-ceramic binder and at least one other component selected from a metal powder, a metal oxide powder and mixtures thereof, and pyrolysing the composition, to form a join between the two substrates, the join comprising a mixed metal oxide. The composition is capable of joining together a wide variety of substrates, without failure, after exposure to high temperature.

Abstract: The compounds of the instant invention are bicyclic or tricyclic amino acids useful in the treatment of fibromylagia. Pharmaceutical compositions containing one or more of the compounds for use in the treatment of fibromyalgia are also included.

Abstract: GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. The compounds are of the formula (III) In the above formula: P represents hydrogen or methyl; Q represents a labile amine- or amide-forming organic group that becomes removed in the human or animal body; R1 represents straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl; R2 represents hydrogen or methyl; and R3 represents hydrogen, methyl or carboxyl; and R4 represents hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body. In the above formula when R1 is phenyl, R2, R3 and R4 are not simultaneously hydrogen.

Abstract: Pro-drug compounds of the formula (I) or (II) and compositions containing them are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. In the above formulae n, P, Q, R1, R2; and R3; are as defined in the specification. The compounds may be used to treat a range of neurological conditions. e.g. epilepsy or pain.

Abstract: This invention relates to novel heterocyclic derivatives of the formula (VII), (VIII) or (IX) 1

Abstract: GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present.

Abstract: The compounds of the instant invention are bicyclic or tricyclic amino acids useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders, and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.

Abstract: Quinolone derivatives of formula (1) are described: 1